Fractyl Health (NASDAQ:GUTS) said it remains on track to report pivotal data for its Revita therapy in early fourth quarter 2026, as management highlighted clinical, regulatory and reimbursement developments during the company’s first-quarter 2026 earnings call.
Chief Executive Officer Dr. Harith Rajagopalan framed Revita as a potential treatment option for patients who discontinue GLP-1 therapies and then face weight regain. He said more than 1 million people discontinue GLP-1s each month in the U.S., and cited weight regain of roughly 10% of total body weight within six months and 15% by 12 months after stopping therapy.
